AKT1 and hematologic disorder: EGF application is able to enhance VEGF-A production and to induce PI3K-dependent positive feedback on AKT and ERK via VEGFR2 in hematological malignancies (human monocytic leukemia THP1 cell line and Burkitt’s lymphoma Raji cell line (Saryeddine et al., 2016).